FOXP3 and rheumatoid arthritis: The anti-arthritic efficacy of BV therapy was shown to be directly attributable to bvPLA2, one of the main components of BV, and this effect was closely associated with expansion of CD25+ Foxp3+ Tregs in the mouse model of RA.